当前位置:科学网首页 > 小柯机器人 >详情
戒酒药物或许能用来减肥
作者:小柯机器人 发布时间:2020/5/17 12:37:25

美国国立卫生研究院的Rafael de Cabo、Michel Bernier等研究人员合作发现,双硫仑治疗可使肥胖小鼠的体重正常化。相关论文于2020年5月14日在线发表在《细胞—代谢》上。

研究人员表示,肥胖是目前社会最重要的公共健康问题。长期食用高脂和高碳水化合物饮食会诱发氧化应激并造成线粒体损伤,最终导致慢性低度炎症并引发组织结构改变。对于许多肥胖的个人,行为和生活方式的改变不足长期保持体重减轻很有效,因此,依靠手术和药物干预。
 
目前,当前美国FDA批准的用于肥胖管理的减肥药物包括奥利司他、洛卡斯汀、芬特明、安非他酮、二甲双胍、纳曲酮和利拉鲁肽。但是,与减肥需要长期使用安全有效的药物,在理想情况下,这些药物可以减轻肥胖合并症,例如改善全身的葡萄糖和脂质稳态。因此,当前社会迫切需要一种可以安全治疗肥胖的药物分子。双硫仑(商业名为Antabuse)是FDA批准的用于治疗慢性酒精成瘾的药物,具有抗炎特性,也有助于预防某些类型的癌症。
 
研究人员发现,在小鼠中双硫仑治疗可防止体重增加,并消除了致肥胖饮食对胰岛素反应性的不利影响,同时减轻了肝脂肪变性和胰岛肥大。此外,双硫仑治疗可逆转中年小鼠饮食引起的肥胖和代谢功能障碍。饲喂效率的降低和能量消耗的增加与长期双硫仑治疗引起的体重改变有关。在使用双硫仑的大鼠中研究人员也观察到脂肪组织的丢失。由于啮齿类动物本身具有强大的肥胖抵御能力,因此在临床上重新应用双硫仑可能是一种治疗肥胖症及其代谢合并症的新策略。
 
附:英文原文

Title: Disulfiram Treatment Normalizes Body Weight in Obese Mice

Author: Michel Bernier, Sarah J. Mitchell, Devin Wahl, Antonio Diaz, Abhishek Singh, Wonhyo Seo, Mingy Wang, Ahmed Ali, Tamzin Kaiser, Nathan L. Price, Miguel A. Aon, Eun-Young Kim, Michael A. Petr, Huan Cai, Alessa Warren, Clara Di Germanio, Andrea Di Francesco, Ken Fishbein, Vince Guiterrez, Dylan Harney, Yen Chin Koay, John Mach, Ignacio Navas Enamorado, Tamara Pulpitel, Yushi Wang, Jing Zhang, Li Zhang, Richard G. Spencer, Kevin G. Becker, Josephine M. Egan, Edward G. Lakatta, John O’Sullivan, Mark Larance, David G. LeCouteur, Victoria C. Cogger, Bin Gao, Carlos Fernandez-Hernando, Ana Maria Cuervo, Rafael de Cabo

Issue&Volume: 2020-05-14

Abstract: Obesity is a top public health concern, and a molecule that safely treats obesityis urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatmentfor chronic alcohol addiction, exhibits anti-inflammatory properties and helps protectagainst certain types of cancer. Here, we show that in mice disulfiram treatment preventedbody weight gain and abrogated the adverse impact of an obesogenic diet on insulinresponsiveness while mitigating liver steatosis and pancreatic islet hypertrophy.Additionally, disulfiram treatment reversed established diet-induced obesity and metabolicdysfunctions in middle-aged mice. Reductions in feeding efficiency and increases inenergy expenditure were associated with body weight regulation in response to long-termdisulfiram treatment. Loss of fat tissue and an increase in liver fenestrations werealso observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents,repurposing disulfiram in the clinic could represent a new strategy to treat obesityand its metabolic comorbidities.

DOI: 10.1016/j.cmet.2020.04.019

Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30236-9

期刊信息

Cell Metabolism:《细胞—代谢》,创刊于2005年。隶属于细胞出版社,最新IF:22.415
官方网址:https://www.cell.com/cell-metabolism/home
投稿链接:https://www.editorialmanager.com/cell-metabolism/default.aspx